Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

Video

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms (MPNs).

In recent years, cellular therapy has evolved rapidly in lymphoid malignancies, especially in lymphoma and ​multiple myeloma, says Mesa.

Notably, at the Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Paul ​J. Shaughnessy, MD, of Methodist Hospital, expanded on these data and provided insight on future directions of CAR T-cell therapy ​in hematologic malignancies.

The utility of cellular-based therapy, in both hematologic and non-hematologic malignancies, has sparked great interest ​across oncology. Encouraging data suggest CAR T-cell therapy may soon find a place in the MPNs space, ​concludes Mesa.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.